Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Regeneron Pharmaceuticals
(NQ:
REGN
)
534.91
+9.91 (+1.89%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jul 1, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Regeneron Pharmaceuticals
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Regeneron to Report Second Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on August 1, 2025
June 26, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Announces First-of-its-Kind Donation Matching Program with Independent Charitable Patient Assistance Organization
June 24, 2025
Initiative aims to expand and encourage philanthropy to help patients with retinal diseases afford their medications
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the Only Targeted Medicine to Treat Patients with Bullous Pemphigoid (BP)
June 20, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Demonstrated Superiority Over Xolair® (Omalizumab) in Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) in Patients with Coexisting Asthma in First-ever Presented Phase 4 Head-to-Head Respiratory Trial
June 15, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
23andMe Reaches Agreement for Sale of Business to TTAM Research Institute Following Final Round of Bidding in Court-Approved Sale Process
June 13, 2025
From
23andMe, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Data at Revolutionizing Atopic Dermatitis (RAD) Conference Reinforce Use in Atopic Dermatitis Patients with Skin of Color
June 07, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Expands Clinical-Stage Obesity Portfolio with Strategic In-Licensing of Novel Dual GLP-1/GIP Receptor Agonist
June 02, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Interim Results from Ongoing Phase 2 COURAGE Trial Confirm Potential to Improve the Quality of Semaglutide (GLP-1 receptor agonist)-induced Weight Loss by Preserving Lean Mass
June 02, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Libtayo® (cemiplimab) Phase 3 Data in the Adjuvant Treatment of Post-Surgical High-Risk Cutaneous Squamous Cell Carcinoma (CSCC) Have Potential to Be Practice-Changing
May 31, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Itepekimab Met Primary Endpoint in One of Two Chronic Obstructive Pulmonary Disease (COPD) Phase 3 Trials
May 30, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Linvoseltamab in Combination with Carfilzomib or Bortezomib Shows Promising Initial Results in Earlier Lines of Treatment for Relapsed/Refractory Multiple Myeloma
May 22, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Enters into Asset Purchase Agreement to Acquire 23andMe® for $256 Million; Plans to Maintain Consumer Genetics Business and Advance Shared Goals of Improving Human Health and Wellness
May 19, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron, A Leading U.S. Biotechnology Company, to Acquire 23andMe in Court-Supervised Sale
May 19, 2025
From
23andMe, Inc.
Via
GlobeNewswire
75th Annual Regeneron International Science and Engineering Fair Awards Teen Scientists from Around the World More Than $9 Million in 2025 Competition
May 16, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Prevails over Amgen in Antitrust PCSK9 Lawsuit Protecting Biotech Innovation and Patient Access to Life-Saving Treatments
May 15, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination
May 01, 2025
18 presentations across five cancer types include new insights on the potential of checkpoint inhibitors and bispecific antibodies
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases
May 01, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Reports First Quarter 2025 Financial and Operating Results
April 29, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Lynozyfic™ (linvoseltamab) Approved in the European Union for the Treatment of Relapsed/Refractory Multiple Myeloma
April 28, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
EYLEA HD® (aflibercept) Injection 8 mg Presentations at ARVO Reinforce Continued Safety and Efficacy and Highlight Early Real-World Outcomes for Patients with Serious Retinal Disease
April 28, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Announces New Investment in Manufacturing of its Industry-Leading Biologic Medicines
April 22, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Announces Investor Conference Presentations
April 21, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Provides Update on EYLEA HD® (aflibercept) Injection 8 mg Supplemental Biologics License Application
April 18, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved in the U.S. as the First New Targeted Therapy in Over a Decade for Chronic Spontaneous Urticaria (CSU)
April 18, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
EYLEA HD® (aflibercept) Injection 8 mg sBLA Accepted for FDA Priority Review for Both the Treatment of Macular Edema Following Retinal Vein Occlusion (RVO) and for Monthly Dosing in Approved Indications
April 17, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Dupixent® (dupilumab) Approved as the First-ever Biologic Medicine in Japan for Patients with Chronic Obstructive Pulmonary Disease (COPD)
March 28, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron to Report First Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2025
March 25, 2025
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Regeneron Science Talent Search 2025 Awards More Than $1.8 Million to High School Seniors for Innovative Scientific Research on Classifying Objects in Space, Treating a Rare Muscle Disease and Solving a Long-Standing Math Problem
March 11, 2025
$250,000 top award goes to Matteo Paz in America’s longest running and most distinguished science and math competition
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
REGN DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Regeneron Pharmaceuticals, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important March 10 Deadline in Securities Class Action – REGN
March 10, 2025
From
The Rosen Law Firm PA
Via
GlobeNewswire
REGN Investors Have Opportunity to Lead Regeneron Pharmaceuticals, Inc. Securities Fraud Lawsuit with the Schall Law Firm
March 10, 2025
From
The Schall Law Firm
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms Of Service
.